ヨーロッパの運動失調症市場 – 業界動向と2029年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

ヨーロッパの運動失調症市場 – 業界動向と2029年までの予測

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Europe
  • 350 ページ
  • テーブル数: 467
  • 図の数: 48

>ヨーロッパの運動失調症市場、タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療と診断)、剤形別(固形、液体、その他)、投与経路別(経口、非経口、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他) - 2029年までの業界動向と予測。

ヨーロッパの運動失調症市場

ヨーロッパ市場の分析と洞察 

運動失調症の罹患率の増加により、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。この重要な時期に、主要な市場プレーヤーは製品の発売と承認に非常に注力しています。さらに、政府と規制当局は、急増する新興疾患に対する製品承認によって市場プレーヤーをサポートしています。

ヨーロッパの運動失調症市場

ヨーロッパの運動失調症市場

ヨーロッパの運動失調症市場は、市場プレーヤーの増加と高度な製品の利用可能性により、予測年度に成長しています。これに伴い、メーカーは市場に新製品を投入するための研究開発活動に取り組んでいます。運動失調症治療の分野での研究の増加と、アルコール消費と薬物使用の増加により、市場の成長がさらに促進されると予想されます。ただし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設が不足しているため、予測期間中のヨーロッパの運動失調症市場の成長が妨げられる可能性があります。

医療費の増加と市場プレーヤーによる戦略的取り組みにより、市場には治療を強化する機会がもたらされる可能性があります。ただし、医薬品や製品の承認に関連する厳格な規則や規制、さまざまな企業による製品リコールが、市場の成長を妨げると予想されます。

ヨーロッパの運動失調症市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に5.8%のCAGRで成長し、2021年の7,424.22千米ドルから2029年には11,169.71千米ドルに達すると分析しています。

レポートメトリック

詳細

予測期間

2022年から2029年

基準年

2021

歴史的な年

2020

定量単位

収益は1000米ドル、価格は米ドル

対象セグメント

タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療および診断)、剤形別(固形剤、液体剤、その他)、投与経路別(経口剤、非経口剤、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他)

対象国

ドイツ、フランス、イギリス、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、オーストリア、ノルウェー、ハンガリー、リトアニア、アイルランド、ポーランド、その他のヨーロッパ諸国

対象となる市場プレーヤー

Novartis AG、Merck KGaA、Aurobindo Pharma、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.、Acorda Therapeutics、Inc.、Viatris Inc.、Sun Pharmaceutical Industries Ltd.、Lupin、Amneal Pharmaceuticals LLC、Cipla Inc.、Intrabio、Biohaven Pharmaceuticals、Priory、その他

市場の定義

運動失調症は、協調運動、バランス、発話に影響を及ぼす一連の障害を指す用語です。どの部位にも影響が出る可能性がありますが、運動失調症の人はバランス、歩行、発話、嚥下、および書くこと、食べること、視覚など高度な制御を必要とする作業に困難を抱えることがよくあります。正確な症状とその重症度は、患者の運動失調症の種類によって異なります。

運動失調症は通常、脳の小脳と呼ばれる部分の損傷によって起こりますが、神経系の他の部分の損傷によっても起こることがあります。この損傷は、MS (多発性硬化症) などの基礎疾患の一部である場合もあれば、頭部外傷、脳への酸素不足、長期にわたる過度のアルコール摂取によって起こる場合もあります。遺伝性運動失調症は、影響を受けるかどうかは不明ですが、家族から受け継がれた欠陥遺伝子によって引き起こされます。

ヨーロッパの運動失調症市場の動向

ドライバー

  • 運動失調症の有病率と発症率の増加

運動失調症は、運動と協調性に影響を与える神経系に関連する神経疾患のグループを指す用語です。運動失調症の人は、バランス、協調性、嚥下、発話に問題を抱えることがよくあります。運動失調症は通常、運動を調整する小脳である脳の一部が損傷することで発症します。これはまれな病気ですが、その発症は世界中で非常に多く見られます。この病気は世界中で大きな臨床問題として広く認識されており、罹患率と死亡率の負担が大きくなっています。そのため、さまざまな年齢層に影響を与える運動失調症の罹患率と発症率の増加が、ヨーロッパの運動失調症市場を牽引しています。

  • 自己免疫疾患の発症数の増加

多発性硬化症などの自己免疫疾患も、持続性運動失調症の原因の 1 つです。多発性硬化症 (MS) は、脳と脊髄 (中枢神経系) に障害を引き起こす可能性のある疾患です。MS では、免疫系が神経線維を覆う保護鞘 (ミエリン) を攻撃し、脳と体の他の部分との間のコミュニケーションに問題を引き起こします。運動失調症を引き起こすこのような自己免疫疾患は、この地域で増加しています。

機会

  • 医療費の増大

各国の人々の可処分所得が増加しているため、医療費は世界中で増加しています。さらに、人口の要件を満たすために、政府機関と医療機関は医療費の加速化に積極的に取り組んでいます。医療費の増加は同時に、近年この疾患が蔓延しているため、医療現場が運動失調症の治療設備を改善するのにも役立っています。

また、主要な市場プレーヤーが講じる戦略的取り組みは、2022~2029年の予測期間において、ヨーロッパの運動失調症市場に構造的完全性と将来の機会をもたらすでしょう。

制約/課題

しかし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設も不足しているため、ヨーロッパの運動失調症市場の成長率は低下するでしょう。さらに、厳しい規則や規制が予測期間の市場にさらなる課題をもたらすでしょう。

このヨーロッパの運動失調症市場レポートでは、最近の新しい開発、貿易規制、輸出入分析、生産分析、バリュー チェーンの最適化、市場シェア、国内および現地の市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。ヨーロッパの運動失調症市場に関する詳細情報を取得するには、アナリスト ブリーフについて Data Bridge Market Research にお問い合わせください。当社のチームが、市場の成長を達成するための情報に基づいた市場決定を行うお手伝いをいたします。

COVID-19後の欧州運動失調症市場への影響

COVID-19は市場にプラスの影響を与えています。パンデミック中のロックダウンと隔離は、病気の管理と服薬遵守を複雑にします。そのため、さまざまな治療薬が世界中の人口に広く増加しています。したがって、パンデミックはこの市場にプラスの影響を与えています。

最近の開発

  • 2017年1月、オーロビンドファーマはポルトガルのジェネリスファーマセウティカSA社を買収したことを発表しました。この会社はポルトガルの大手医薬品メーカーです。この買収により、同社は世界的なプレゼンスを高めることができました。

ヨーロッパの運動失調症市場の範囲

ヨーロッパの運動失調症市場は、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネルに区分されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。

タイプ

  • 脊髄小脳失調症
  • 毛細血管拡張性運動失調症
  • 発作性運動失調症
  • その他(多系統萎縮症(MSA))

タイプに基づいて、ヨーロッパの運動失調症市場は、脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA))に分類されます。

製品

  • 診断
  • 処理

製品に基づいて、ヨーロッパの運動失調症市場は治療と診断に分類されます。

剤形

  • 固体
  • 液体
  • その他

剤形に基づいて、ヨーロッパの運動失調症市場は、固体、液体、その他に分類されます。

投与経路

  • オーラル     
  • 非経口
  • その他

投与経路に基づいて、ヨーロッパの運動失調症市場は経口、非経口、その他に分類されます。

患者タイプ

  • アダルト
  • 子供
  • 老年病

患者タイプに基づいて、ヨーロッパの運動失調症市場は、成人、小児、高齢者に分類されます。

エンドユーザー

  • 病院
  • クリニック
  • 在宅医療
  • その他

エンドユーザーに基づいて、ヨーロッパの運動失調症市場は、病院、診療所、在宅医療、その他に分類されます。

流通チャネル

  • 直接入札
  • 小売販売
  • その他

ヨーロッパの運動失調症市場

流通チャネルに基づいて、ヨーロッパの運動失調症市場は、直接入札、小売販売、その他に分類されます。

ヨーロッパの運動失調症市場の地域分析/洞察                 

ヨーロッパの運動失調症市場が分析され、市場規模の洞察と傾向が国、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネル別に提供されます。

この地域に含まれる国には、ドイツ、フランス、イギリス、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、オーストリア、ノルウェー、ハンガリー、リトアニア、アイルランド、ポーランド、その他のヨーロッパ諸国などがあります。ドイツは、市場シェアと収益の面でヨーロッパの運動失調症市場を支配すると予想されており、予測期間中もその優位性を維持し続けるでしょう。これは、この地域での運動失調症の有病率が高く、アルコールの使用量が多いためです。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。

競争環境とヨーロッパの運動失調症市場シェア分析

ヨーロッパの運動失調症市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、ヨーロッパの運動失調症市場における会社の焦点にのみ関連しています。

ヨーロッパの運動失調症市場で活動している主要企業としては、Novartis AG、Merck KGaA、Aurobindo Pharma、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.、Acorda Therapeutics, Inc.、Viatris Inc.、Sun Pharmaceutical Industries Ltd.、Lupin.、Amneal Pharmaceuticals LLC.、Cipla Inc.、Intrabio、Biohaven Pharmaceuticals、Priory などが挙げられます。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、ヨーロッパと地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE ATAXIA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

4.3 EPIDEMIOLOGY

5 PIPELINE ANALYSIS

6 EUROPE ATAXIA MARKET: REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA

7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS

7.1.3 RISE IN ALCOHOL AND DRUG USAGE

7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE

7.2 RESTRAINTS

7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE

7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES

7.3 OPPORTUNITIES

7.3.1 RISING HEALTHCARE EXPENDITURE

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 STRINGENT RULES AND REGULATIONS

7.4.2 PRODUCT RECALL

8 EUROPE ATAXIA MARKET, BY TYPE

8.1 OVERVIEW

8.2 SPINOCEREBELLAR ATAXIAS

8.2.1 TYPE 3

8.2.2 TYPE 2

8.2.3 TYPE 1

8.2.4 OTHERS

8.3 ATAXIA-TELANGIECTASIA

8.4 EPISODIC ATAXIA

8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))

9 EUROPE ATAXIA MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 TREATMENT

9.2.1 PHARMACOTHERAPY

9.2.1.1 STIFFNESS/SPASTICITY

9.2.1.1.1 GABAPENTIN

9.2.1.1.2 LEVODOPA

9.2.1.1.3 OTHERS

9.2.1.2 GAIT AND TREMORS

9.2.1.2.1 VARENICLINE

9.2.1.2.2 RILUZOLE

9.2.1.2.3 AMANTADINE

9.2.1.2.4 OTHERS

9.2.1.3 ANTI-OXIDANTS

9.2.1.3.1 N‐ACETYLCYSTEINE

9.2.1.3.2 SELEGILINE

9.2.1.3.3 DEHYDROEPIANDROSTERONE

9.2.1.3.4 VITAMIN E

9.2.1.4 NON ANTI-OXIDANTS

9.2.1.4.1 ERYTHROPOIETIN

9.2.1.4.2 DEFERIPRONE

9.2.1.4.3 RESVERATROL

9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS

9.2.1.5 ANTI-ARRHYTHMIC AGENTS

9.2.1.5.1 AMIODARONE

9.2.1.5.2 PROPAFENONE

9.2.1.5.3 FLECAINIDE

9.2.1.5.4 IBUTILIDE

9.2.1.6 ANTI-CARDIAC FAILURE

9.2.1.6.1 BENAZEPRIL

9.2.1.6.2 LISINOPRIL

9.2.1.6.3 CAPTOPRIL

9.2.1.6.4 ENALAPRIL

9.2.1.6.5 FOSINOPRIL

9.2.1.6.6 MOEXIPRIL

9.2.1.6.7 OTHERS

9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS

9.2.1.7.1 BIGUANIDES (METFORMIN)

9.2.1.7.2 SULFONYLUREAS

9.2.1.7.2.1 GLIPIZIDE

9.2.1.7.2.2 GLIMEPIRIDE

9.2.1.7.2.3 GLYBURIDE

9.2.1.7.2.4 OTHERS

9.2.1.7.3 THIAZOLIDINEDIONES

9.2.1.7.4 MEGLITINIDES

9.2.2 LIFESTYLE THERAPY

9.2.2.1 PHYSICAL THERAPY

9.2.2.2 SPEECH THERAPY

9.2.2.3 PALLIATIVE CARE

9.2.2.4 OTHERS

9.2.3 SUPPORTIVE DEVICES

9.2.3.1 WALKING AIDS

9.2.3.2 WHEELCHAIRS

9.2.3.3 OTHERS

9.3 DIAGNOSTICS

9.3.1 IMAGING TEST

9.3.1.1 MRI SCAN

9.3.1.2 OTHERS

9.3.2 BLOOD TEST

9.3.3 GENETIC TESTING

10 EUROPE ATAXIA MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 SOLID

10.2.1 TABLETS

10.2.2 CAPSULES

10.2.3 OTHERS

10.3 LIQUIDS

10.3.1 INJECTION

10.3.2 SOLUTIONS

10.3.3 OTHERS

10.4 OTHERS

11 EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 PARENTERAL

11.4 OTHERS

12 EUROPE ATAXIA MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ADULT

12.2.1 MALE

12.2.2 FEMALE

12.3 CHILD

12.4 GERIATRIC

13 EUROPE ATAXIA MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.3.1 HOSPITAL PHARMACY

14.3.2 RETAIL SHOP

14.3.3 ONLINE PHARMACY

14.4 OTHERS

15 EUROPE ATAXIA MARKET, BY GEOGRAPHY

15.1 EUROPE

15.1.1 GERMANY

15.1.2 U.K.

15.1.3 FRANCE

15.1.4 ITALY

15.1.5 SPAIN

15.1.6 SWITZERLAND

15.1.7 NETHERLANDS

15.1.8 IRELAND

15.1.9 RUSSIA

15.1.10 HUNGARY

15.1.11 AUSTRIA

15.1.12 NORWAY

15.1.13 POLAND

15.1.14 TURKEY

15.1.15 LITHUANIA

15.1.16 REST OF EUROPE

16 EUROPE ATAXIA MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 SELECT MEDICAL CORPORATION

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NOVARTIS AG

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 AMNEAL PHARMACEUTICALS LLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLI

18.4.5 RECENT DEVELOPMENT

18.5 UPSTREAM REHABILITATION INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 PRIORY

18.6.1 COMPANY SNAPSHOT

18.6.2 COMPANY SHARE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ACORDA THERAPEUTICS, INC.

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 ADVERUM BIOTECHNOLOGIES, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 APOTEX INC.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 ATI PHYSICAL THERAPY

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 AUROBINDO PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 BANNER HEALTH

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 BIOHAVEN PHARMACEUTICALS

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 BIOVISTA

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 CIPLA INC.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 DESIGN THERAPEUTICS, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 INTRABIO

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENT

18.18 LUPIN.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 MATRIX BIOMED

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 MERCK KGAA

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENTS

18.21 REATA PHARMACEUTICALS, INC.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 RETROTOPE INC.

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.23 SANOFI

18.23.1 COMPANY SNAPSHOT

18.23.2 REVENUE ANALYSIS

18.23.3 PRODUCT PORTFOLIO

18.23.4 RECENT DEVELOPMENT

18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

18.25 SUTTER HEALTH

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENTS

18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENT

18.27 VIATRIS INC.

18.27.1 COMPANY SNAPSHOT

18.27.2 REVENUE ANALYSIS

18.27.3 PRODUCT PORTFOLIO

18.27.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表のリスト

TABLE 1  EUROPE ATAXIA MARKET: PIPELINE ANALYSIS

TABLE 2  EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3  EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4  EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5  EUROPE ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6  EUROPE EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7  EUROPE OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8  EUROPE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 9  EUROPE TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 10  EUROPE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 11  EUROPE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 12  EUROPE STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 13  EUROPE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 14  EUROPE ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 15  EUROPE NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 16  EUROPE ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 17  EUROPE ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 18  EUROPE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 19  EUROPE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 20  EUROPE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 21  EUROPE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 22  EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23  EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 24  EUROPE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 25  EUROPE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 26  EUROPE SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27  EUROPE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 28  EUROPE LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29  EUROPE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 30  EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31  EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 32  EUROPE ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33  EUROPE PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34  EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35  EUROPE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 36  EUROPE ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37  EUROPE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 38  EUROPE CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39  EUROPE GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40  EUROPE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41  EUROPE HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42  EUROPE CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43  EUROPE HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44  EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45  EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 46  EUROPE DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 47  EUROPE RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48  EUROPE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 49  EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50  EUROPE ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 51  EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 52  EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 53  EUROPE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 54  EUROPE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 55  EUROPE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 56  EUROPE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57  EUROPE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58  EUROPE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59  EUROPE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60  EUROPE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61  EUROPE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62  EUROPE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63  EUROPE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64  EUROPE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65  EUROPE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66  EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67  EUROPE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68  EUROPE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 69  EUROPE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 70  EUROPE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 71  EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 72  EUROPE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 73  EUROPE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 74  EUROPE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 75  EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 76  EUROPE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 77  GERMANY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 78  GERMANY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 79  GERMANY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 80  GERMANY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 81  GERMANY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82  GERMANY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83  GERMANY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84  GERMANY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85  GERMANY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86  GERMANY ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87  GERMANY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88  GERMANY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89  GERMANY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90  GERMANY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91  GERMANY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92  GERMANY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93  GERMANY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 94  GERMANY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 95  GERMANY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 96  GERMANY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 97  GERMANY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 98  GERMANY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 99  GERMANY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 100  GERMANY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101  GERMANY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102  GERMANY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103  U.K. ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 104  U.K. SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 105  U.K. ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 106  U.K. TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107  U.K. PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108  U.K. STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109  U.K. GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110  U.K. ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111  U.K. NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112  U.K. ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113  U.K. ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114  U.K. ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115  U.K. SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116  U.K. LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117  U.K. SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118  U.K. DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 119  U.K. IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 120  U.K. ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 121  U.K. SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122  U.K. LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123  U.K. ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 124  U.K. ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 125  U.K. ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 126  U.K. ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 127  U.K. ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 128  U.K. RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 129  FRANCE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 130  FRANCE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 131  FRANCE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 132  FRANCE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133  FRANCE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134  FRANCE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135  FRANCE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136  FRANCE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137  FRANCE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138  FRANCE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139  FRANCE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140  FRANCE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141  FRANCE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142  FRANCE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143  FRANCE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 144  FRANCE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 145  FRANCE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 146  FRANCE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 147  FRANCE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 148  FRANCE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 149  FRANCE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 150  FRANCE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 151  FRANCE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 152  FRANCE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 153  FRANCE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 154  FRANCE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155  ITALY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 156  ITALY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 157  ITALY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 158  ITALY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 159  ITALY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160  ITALY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161  ITALY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162  ITALY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163  ITALY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164  ITALY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165  ITALY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166  ITALY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167  ITALY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168  ITALY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 169  ITALY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 170  ITALY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 171  ITALY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 172  ITALY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 173  ITALY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 174  ITALY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 175  ITALY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 176  ITALY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 177  ITALY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 178  ITALY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 179  ITALY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 180  ITALY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 181  SPAIN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 182  SPAIN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 183  SPAIN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 184  SPAIN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 185  SPAIN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186  SPAIN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187  SPAIN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188  SPAIN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189  SPAIN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190  SPAIN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191  SPAIN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192  SPAIN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193  SPAIN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 194  SPAIN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 195  SPAIN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 196  SPAIN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 197  SPAIN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 198  SPAIN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 199  SPAIN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 200  SPAIN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 201  SPAIN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 202  SPAIN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 203  SPAIN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 204  SPAIN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 205  SPAIN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 206  SPAIN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 207  SWITZERLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 208  SWITZERLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 209  SWITZERLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 210  SWITZERLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 211  SWITZERLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 212  SWITZERLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 213  SWITZERLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 214  SWITZERLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 215  SWITZERLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 216  SWITZERLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 217  SWITZERLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 218  SWITZERLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 219  SWITZERLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 220  SWITZERLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 221  SWITZERLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 222  SWITZERLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 223  SWITZERLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 224  SWITZERLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 225  SWITZERLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 226  SWITZERLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 227  SWITZERLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 228  SWITZERLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 229  SWITZERLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 230  SWITZERLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 231  SWITZERLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 232  SWITZERLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 233  NETHERLANDS ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 234  NETHERLANDS SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 235  NETHERLANDS ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 236  NETHERLANDS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 237  NETHERLANDS PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 238  NETHERLANDS STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 239  NETHERLANDS GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 240  NETHERLANDS ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 241  NETHERLANDS NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 242  NETHERLANDS ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 243  NETHERLANDS ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 244  NETHERLANDS ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 245  NETHERLANDS SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 246  NETHERLANDS LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 247  NETHERLANDS SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 248  NETHERLANDS DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 249  NETHERLANDS IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 250  NETHERLANDS ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 251  NETHERLANDS SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 252  NETHERLANDS LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 253  NETHERLANDS ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 254  NETHERLANDS ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 255  NETHERLANDS ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 256  NETHERLANDS ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 257  NETHERLANDS ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 258  NETHERLANDS RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 259  IRELAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 260  IRELAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 261  IRELAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 262  IRELAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 263  IRELAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 264  IRELAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 265  IRELAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 266  IRELAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 267  IRELAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 268  IRELAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 269  IRELAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 270  IRELAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 271  IRELAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 272  IRELAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 273  IRELAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 274  IRELAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 275  IRELAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 276  IRELAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 277  IRELAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 278  IRELAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 279  IRELAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 280  IRELAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 281  IRELAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 282  IRELAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 283  IRELAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 284  IRELAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 285  RUSSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 286  RUSSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 287  RUSSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 288  RUSSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 289  RUSSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 290  RUSSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 291  RUSSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 292  RUSSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 293  RUSSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 294  RUSSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 295  RUSSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 296  RUSSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 297  RUSSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 298  RUSSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 299  RUSSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 300  RUSSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 301  RUSSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 302  RUSSIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 303  RUSSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 304  RUSSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 305  RUSSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 306  RUSSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 307  RUSSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 308  RUSSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 309  RUSSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 310  RUSSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 311  HUNGARY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 312  HUNGARY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 313  HUNGARY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 314  HUNGARY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 315  HUNGARY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 316  HUNGARY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 317  HUNGARY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 318  HUNGARY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 319  HUNGARY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 320  HUNGARY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 321  HUNGARY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 322  HUNGARY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 323  HUNGARY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 324  HUNGARY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 325  HUNGARY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 326  HUNGARY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 327  HUNGARY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 328  HUNGARY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 329  HUNGARY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 330  HUNGARY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 331  HUNGARY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 332  HUNGARY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 333  HUNGARY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 334  HUNGARY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 335  HUNGARY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 336  HUNGARY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 337  AUSTRIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 338  AUSTRIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 339  AUSTRIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 340  AUSTRIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 341  AUSTRIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 342  AUSTRIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 343  AUSTRIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 344  AUSTRIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 345  AUSTRIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 346  AUSTRIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 347  AUSTRIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 348  AUSTRIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 349  AUSTRIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 350  AUSTRIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 351  AUSTRIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 352  AUSTRIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 353  AUSTRIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 354  AUSTRIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 355  AUSTRIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 356  AUSTRIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 357  AUSTRIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 358  AUSTRIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 359  AUSTRIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 360  AUSTRIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 361  AUSTRIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 362  AUSTRIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 363  NORWAY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 364  NORWAY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 365  NORWAY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 366  NORWAY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 367  NORWAY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 368  NORWAY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 369  NORWAY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 370  NORWAY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 371  NORWAY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 372  NORWAY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 373  NORWAY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 374  NORWAY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 375  NORWAY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 376  NORWAY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 377  NORWAY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 378  NORWAY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 379  NORWAY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 380  NORWAY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 381  NORWAY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 382  NORWAY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 383  NORWAY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 384  NORWAY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 385  NORWAY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 386  NORWAY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 387  NORWAY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 388  NORWAY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 389  POLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 390  POLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 391  POLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 392  POLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 393  POLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 394  POLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 395  POLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 396  POLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 397  POLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 398  POLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 399  POLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 400  POLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 401  POLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 402  POLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 403  POLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 404  POLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 405  POLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 406  POLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 407  POLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 408  POLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 409  POLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 410  POLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 411  POLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 412  POLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 413  POLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 414  POLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 415  TURKEY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 416  TURKEY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 417  TURKEY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 418  TURKEY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 419  TURKEY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 420  TURKEY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 421  TURKEY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 422  TURKEY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 423  TURKEY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 424  TURKEY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 425  TURKEY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 426  TURKEY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 427  TURKEY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 428  TURKEY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 429  TURKEY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 430  TURKEY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 431  TURKEY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 432  TURKEY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 433  TURKEY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 434  TURKEY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 435  TURKEY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 436  TURKEY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 437  TURKEY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 438  TURKEY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 439  TURKEY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 440  TURKEY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 441  LITHUANIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 442  LITHUANIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 443  LITHUANIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 444  LITHUANIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 445  LITHUANIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 446  LITHUANIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 447  LITHUANIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 448  LITHUANIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 449  LITHUANIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 450  LITHUANIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 451  LITHUANIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 452  LITHUANIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 453  LITHUANIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 454  LITHUANIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 455  LITHUANIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 456  LITHUANIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 457  LITHUANIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 458  LITHUANIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 459  LITHUANIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 460  LITHUANIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 461  LITHUANIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 462  LITHUANIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 463  LITHUANIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 464  LITHUANIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 465  LITHUANIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 466  LITHUANIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 467  REST OF EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

図表一覧

FIGURE 1  EUROPE ATAXIA MARKET: SEGMENTATION

FIGURE 2  EUROPE ATAXIA MARKET: DATA TRIANGULATION

FIGURE 3  EUROPE ATAXIA MARKET: DROC ANALYSIS

FIGURE 4  EUROPE ATAXIA MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5  EUROPE ATAXIA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6  EUROPE ATAXIA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7  EUROPE ATAXIA MARKET: DBMR MARKET POSITION GRID

FIGURE 8  EUROPE ATAXIA MARKET: END USER COVERAGE GRID

FIGURE 9  EUROPE ATAXIA MARKET: VENDOR SHARE ANALYSIS

FIGURE 10  EUROPE ATAXIA MARKET: SEGMENTATION

FIGURE 11  RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE EUROPE ATAXIA MARKET IN THE FORECAST PERIOD

FIGURE 12  SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ATAXIA MARKET IN 2022 & 2029

FIGURE 13  NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14  DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ATAXIA MARKET

FIGURE 15  EUROPE ATAXIA MARKET: BY TYPE, 2021

FIGURE 16  EUROPE ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)

FIGURE 17  EUROPE ATAXIA MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 18  EUROPE ATAXIA MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19  EUROPE ATAXIA MARKET: BY PRODUCT, 2021

FIGURE 20  EUROPE ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)

FIGURE 21  EUROPE ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 22  EUROPE ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 23  EUROPE ATAXIA MARKET: BY DOSAGE FORM, 2021

FIGURE 24  EUROPE ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)

FIGURE 25  EUROPE ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 26  EUROPE ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 27  EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 28  EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)

FIGURE 29  EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 30  EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 31  EUROPE ATAXIA MARKET: BY PATIENT TYPE, 2021

FIGURE 32  EUROPE ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)

FIGURE 33  EUROPE ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 34  EUROPE ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 35  EUROPE ATAXIA MARKET: BY END USER, 2021

FIGURE 36  EUROPE ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)

FIGURE 37  EUROPE ATAXIA MARKET: BY END USER, CAGR (2022-2029)

FIGURE 38  EUROPE ATAXIA MARKET: BY END USER, LIFELINE CURVE

FIGURE 39  EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 40  EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)

FIGURE 41  EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 42  EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43  EUROPE ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 44  EUROPE ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 45  EUROPE ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46  EUROPE ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 47  EUROPE ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 48  EUROPE ATAXIA MARKET: COMPANY SHARE 2021 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

Europe Ataxia Market is growing with a CAGR of 5.8% by 2029
Europe Ataxia Market is expected to reach USD 11,169.71 thousand by 2029
The major players operating in the Europe ataxia market are Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics, Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Cipla Inc., Intrabio, Biohaven Pharmaceuticals, Priory., among others.
The difficulty in diagnosing the disease and lack of genetic testing facilities in some developing countries will impede the growth rate